Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis

Dec 3, 2024Sleep

Glucagon-like peptide-1 drugs and their effects on obstructive sleep apnea: a combined analysis

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists (GLP-1RAs) significantly decreased the apnea-hypopnea index by 9.48 events per hour in individuals with obstructive sleep apnea (OSA).

A total of 1067 participants from six studies were included in the analysis.
Weight loss associated with GLP-1RA treatment averaged -10.99 kg.
Body mass index (BMI) decreased by -1.60 kg/m2 with GLP-1RA intervention.
Systolic blood pressure reduced by -4.81 mmHg, while diastolic blood pressure decreased by -0.32 mmHg.
Tirzepatide was more effective than liraglutide, with a greater reduction in apnea-hypopnea index.
Obese individuals showed a more significant decrease in apnea-hypopnea index compared to non-obese individuals.

AI simplified

STUDY OBJECTIVES: Obstructive sleep apnea (OSA) is characterized by disordered breathing during sleep and is associated with major cardiovascular complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as an important treatment for obesity and diabetes mellitus show promising therapeutic prospects in OSA. We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.

METHODS: We searched the PubMed and Web of Science databases (published until July 1, 2024). The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).

RESULTS: Six studies with a total of 1067 participants enrolled. GLP-1RA significantly decreased AHI with an estimated treatment difference of -9.48 events per hour (95% confidence interval [CI] = -12.56 to - 6.40, I2 = 92%). The change in weight was -10.99 kg and body mass index (BMI) was -1.60 kg/m2. The mean difference in systolic blood pressure was -4.81 mmHg and in diastolic blood pressure was -0.32 mmHg. Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI = -25.93 to -17.79) vs -5.10 events per hour (95% CI = -6.95 to -3.26). Obese individuals experienced a more significant decrease in AHI with an estimated treatment difference of -12.93 events per hour vs -4.31 events per hour. The application of continuous positive airway pressure and the duration of follow-up did not affect the therapeutic effect.

CONCLUSIONS: GLP-1RA could significantly reduce the severity of OSA, and also lead to weight loss and lower blood pressure. Further high-quality randomized controlled trials (RCTs) are needed to explore different GLP-1RA treatments and durations in OSA and identify participant subgroups that may benefit the most.

CLINICAL TRIAL: NA.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief